Literature DB >> 15357997

Non-peptide oxytocin agonists.

Gary R W Pitt1, Andrzej R Batt, Robert M Haigh, Andrew M Penson, Peter A Robson, David P Rooker, André L Tartar, Julie E Trim, Christopher M Yea, Michael B Roe.   

Abstract

A library of compounds targeted to the vasopressin/oxytocin family of receptors was screened for activity at a cloned human oxytocin receptor using a reporter gene assay. Potency and selectivity were optimised to afford compound 39, EC50 = 33 nM. This series of compounds represents the first disclosed, non-peptide, low molecular weight agonists of the hormone oxytocin (OT).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15357997     DOI: 10.1016/j.bmcl.2004.04.107

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

Review 1.  The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings.

Authors:  David M Cochran; Daniel Fallon; Michael Hill; Jean A Frazier
Journal:  Harv Rev Psychiatry       Date:  2013 Sep-Oct       Impact factor: 3.732

Review 2.  The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategies.

Authors:  Meera E Modi; Larry J Young
Journal:  Horm Behav       Date:  2011-12-20       Impact factor: 3.587

Review 3.  Neurobiology of sociability.

Authors:  Heather K Caldwell
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

4.  The Current Status of Drug Discovery for the Oxytocin Receptor.

Authors:  Philippe E Nashar; Aidan A Whitfield; Jiri Mikusek; Tristan A Reekie
Journal:  Methods Mol Biol       Date:  2022

Review 5.  REVIEW: Oxytocin: Crossing the bridge between basic science and pharmacotherapy.

Authors:  Cedric Viero; Izumi Shibuya; Naoki Kitamura; Alexei Verkhratsky; Hiroaki Fujihara; Akiko Katoh; Yoichi Ueta; Hans H Zingg; Alexandr Chvatal; Eva Sykova; Govindan Dayanithi
Journal:  CNS Neurosci Ther       Date:  2010-07-07       Impact factor: 5.243

Review 6.  Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.

Authors:  B Mouillac; M Manning; T Durroux
Journal:  Mini Rev Med Chem       Date:  2008-09       Impact factor: 3.862

7.  The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents.

Authors:  Nikolaos Vrachnis; Fotodotis M Malamas; Stavros Sifakis; Efthymios Deligeoroglou; Zoe Iliodromiti
Journal:  Int J Endocrinol       Date:  2011-12-06       Impact factor: 3.257

Review 8.  Role of Oxytocin and Vasopressin in Neuropsychiatric Disorders: Therapeutic Potential of Agonists and Antagonists.

Authors:  Valeska Cid-Jofré; Macarena Moreno; Miguel Reyes-Parada; Georgina M Renard
Journal:  Int J Mol Sci       Date:  2021-11-08       Impact factor: 5.923

Review 9.  Barriers and Breakthroughs in Targeting the Oxytocin System to Treat Alcohol Use Disorder.

Authors:  Andrey E Ryabinin; Yangmiao Zhang
Journal:  Front Psychiatry       Date:  2022-02-28       Impact factor: 4.157

10.  Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.

Authors:  K Macdonald; D Feifel
Journal:  Front Neurosci       Date:  2013-03-15       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.